BioVeda
Home
Investment Policy
People
Investors
Our Companies
Our CEOs
News and Events
2008 News
2007 News
Contact
2007 News
Dec 20
-
Memory Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Dec 6
- MerLion Pharmaceuticals Wins Prestigious Pharmaceutical Industry Scrip Award
Nov 26
- Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9
Nov 2
- Memory Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease
Nov 1
- Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV, an Investigational Hepatitis B Vaccine Currently in Phase 3
Oct 25
-
Paratek Announces the Close of $40 Million Private Placement
Oct 22
- Dynavax Begins TOLAMBA Environmental Exposure Chamber Study
Oct 15
-
Memory Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease
Oct 10
- Kiadis Reports
Successful Independent Clinical Evaluation of ATIR
Oct 10
- Renovo wins European Biotechnica Award
Sep 26
- MerLion initiates Phase 1 clinical study of Finafloxacin
Sep 19
- Dynavax's HEPLISAV Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
Sep 12
- Renovo reports Juvista Phase II Results using Lonza Drug Substance
Aug 31
- Kiadis reports Promising Phase II Results for Reviroc
Aug 29
-
Memory Commences Phase 1 Clinical Program for R4996/MEM 63908
Aug 16
- Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
Aug 7
- Dynavax Awarded $3+ Million Universal Flu Vaccine Grant from NIAID
Jul 18
- Dynavax Receives $30 Million Commitment by Deerfield Management for TLR9 Allergy Franchise
Jul 12
-
Dynavax Completes Enrollment of HEPLISAV(TM) Phase 3
Jul 12
-
Memory Completes Enrollment in Phase 2a MEM 3454 Alzheimer's Disease Trial
Jul 9
-
Warner Chilcott and Paratek Sign Collaboration Agreement for Novel, Narrow-Spectrum Agents for Acne and Rosacea
Jul 9
-
Kiadis Pharma Announces Clinical Study with NIH
Jun 26
-
Kiadis Pharma Raises €15 million to Advance Oncology Pipeline
Jun 20
- Renovo and Shire enter Licensing Agreement To Develop and Commercialise Juvista
Jun 19
-
Memory Announces Equity Funding Led by The Stanley Medical Research Institute
Jun 6
- Fierce Biotech Names MerLion as One of the "Fierce 15" Biotech Companies of 2007
Apr 17
- Renovo Announces Positive Phase 2 Results for Prevascar
Apr 5
-
Memory Completes Enrolment in Phase 2a MEM 1003 Alzheimer's Disease Trial
Mar 27
- First European Results for Kiadis Pharma Lead Product ATIR
Mar 22
- MerLion Pharmaceuticals and Merck Banyu enter a new drug discovery alliance Extension of four-year collaboration with Merck & Co Inc
Mar 19 -
Memory Secures $10 Million Debt Financing
Mar 11
- Neurovision, Essilor in Distribution Deal
Mar 13 -
Memory Commences Phase 2a Trial of MEM 3454 in Alzheimer's Disease
Mar 5 -
Memory Reports Phase 2a Results for MEM 1003 in Bipolar Disorder
Mar 1
-
Dynavax Initiates Phase I Trial of Hepatitis B Therapy
Mar 1
- Mr. David Dally joins MerLion Pharmaceuticals as CFO. MerLion announces the successful closure of its US$30M Series B round of financing
Feb 23
-
Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI
Feb 13
- Dr. Lynn Silver joins MerLion Pharmaceuticals’ Scientific Advisory Board
Jan 18
- Kiadis Pharma Acquires Assets To Develop Novel Cancer Treatments
Jan 8
-
Dynavax Reports Interim TOLAMBA(TM) Ragweed Allergy Results From DARTT Trial
Your Partner in Asia